Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | SDHA | P31040 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CALML3 | P27482 | 1/20 | 1.00 |
| ▸ | F10 | P00742 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linezolid SCHEMBL30226927 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30638355 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL7992562 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL1561095 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5524444 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL374752 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2222512 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2280731 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2279924 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2277149 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31707 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4749288-A1 | COMPOSITIONS FOR DETECTING, CHARACTERIZING, AND REMOVING A BIOFILM | COSA Group GmbH (DE) | 2026-05-27 | — | — | EP | claimed |
| EP-4746883-A1 | COMBINATION PRODUCTS OF AT LEAST THREE ANTIBIOTICS COMPRISING BEDAQUILINE, PRETOMANID OR DELAMANID, AND A CYTOCHROME BC1 INHIBITOR, AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | Janssen Pharmaceutica NV (BE) | 2026-05-27 | — | — | EP | claimed |
| WO-2026106551-A1 | ANTIMICROBIAL PEPTIDE NANONETS AND METHODS OF USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-05-21 | — | — | WO | claimed |
| CN-115215923-B | Macrocyclic broad-spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4742259-A1 | METHOD AND DEVICE FOR PREDICTING THE APPROPRIATENESS OF ANTIBIOTIC USE IN PATIENTS WITH INFECTIOUS DISEASES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260128145-A1 | METHOD AND DEVICE FOR PREDICTING THE APPROPRIATENESS OF ANTIBIOTIC USE IN PATIENTS WITH INFECTIOUS DISEASES | UNIV YONSEI IACF (KR) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2001034128-A2 | ADMIXTURE FOR INTRAVENOUS ADMINISTRATION OF LINEZOLID AND OTHER ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1096934-A1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2001-05-09 | — | — | EP | claimed |
| WO-2001002024-A1 | AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS | SINUSPHARMACY INC. (US) | 2001-01-11 | — | — | WO | claimed |
| EP-1032386-A1 | USE OF OXAZOLIDINONE DERIVATITIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000045177-A1 | ASSAYS FOR MODULATORS OF ELONGATION FACTOR P ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-6040306-A | Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy | PHARMACIA & UPJOHN COMPANY | 2000-03-21 | — | — | US | claimed |
| WO-2000003710-A1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-27 | — | — | WO | claimed |
| WO-1999063937-A2 | MULTIVALENT MACROLIDE ANTIBIOTICS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| EP-0717738-B1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1999025344-A1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-27 | — | — | WO | claimed |